Harvard Men's Health Watch

Alzheimer's drug update

Studies of two new Alzheimer's drugs ended in disappointment. Intravenous versions of the drugs failed to help people with mild to moderate Alzheimer's. But the studies also found reason to hope for better results with similar drugs.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In